Search Results

354 Results for "cytodyn".

Sort By

BioForest

CytoDyn to Host Webcast to Provide Company Update

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executive Officer, will host an investment community webcast on Thursday, May 30, 2024.

May 28, 2024
·
4 min read
Drug Development

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

CytoDyn Inc. announced today that its preclinical MASH study with SMC Laboratories, Inc. (“SMC”) has commenced, with results expected in the fall of 2024.

June 27, 2024
·
4 min read
Press Releases

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

November 25, 2024
·
4 min read
Press Releases

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

November 4, 2024
·
3 min read
Press Releases

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories

September 24, 2024
·
2 min read
Press Releases

CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

October 4, 2024
·
3 min read
Press Releases

CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development

October 8, 2024
·
3 min read
Policy

CytoDyn Announces FDA Has Lifted Clinical Hold

CytoDyn Inc., a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the FDA has lifted the clinical hold on leronlimab.

February 29, 2024
·
4 min read
Press Releases

CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories

October 30, 2024
·
4 min read
Press Releases

CytoDyn Engages Leading CRO For Phase II Inflammation Trial

August 26, 2024
·
2 min read